Shabana Z. Shafy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shabana Z. Shafy has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Stephani S. Kim
Department of Anesthesiology & Pain Medicine, Nationwide Children’s Hospital, Columbus, OH, USA
2 shared publications - Giorgio Veneziano
Department of Anesthesiology & Pain Medicine, Nationwide Children’s Hospital, Columbus, OH, USA
1 shared publication Joseph D. Tobias
Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, OH, USA; Department of Anesthesiology & Pain Medicine, The Ohio State University College of Medicine, Columbus, OH, USA; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA
1 shared publication- Joseph Tobias
Section of Endocrine Surgery, Department of Surgery, Boston Medical Center, Boston, MA
1 shared publication - Joshua C. Uffman
Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio
1 shared publication - Lance M. Relland
Department of Anesthesiology, Nationwide Children's Hospital, Columbus, Ohio, USA
1 shared publication
Latest Publications
- 1 April 2022
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 57 (4) , 683-689
Continuous epidural chloroprocaine after abdominal surgery is associated with lower postoperative opioid exposure in NICU infants
- 1 April 2022
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 57 (4) , 683-689
Continuous epidural chloroprocaine after abdominal surgery is associated with lower postoperative opioid exposure in NICU infants
- Open Access
- 1 March 2022
- Published by Elmer Press, Inc. in Journal of Current Surgery
- Vol. 12 (1) , 1-6
Preoperative Administration of Aprepitant to Prevent Postoperative Nausea and Vomiting in Children
Background: Aprepitant (Emend®), a neurokinin-receptor antagonist, has seen increased use in the treatment of nausea and vomiting in various clinical scenarios. To date, there are limited data regarding its use in the pediatric population. We retrospectively reviewed our experience with aprepitant after its addition to the operating room formulary for prevention of postoperative nausea and vomiting (PONV). Methods: The anesthetic records of patients who received aprepitant were retrospectively reviewed. Demographic, surgical, medication, and efficacy data were retrieved. Results: The study cohort included 144 patients ranging in age from 7 to 17 years and in weight from 24.7 to 208.9 kg. The most common surgical procedures included gastrointestinal surgery, orthopedic surgery, and otolaryngologic procedures. Reasons for the administration of aprepitant included PONV prophylaxis due to risk factors such as type of surgery, duration of surgery, previous history of significant PONV, female gender, and family history of PONV. The majority of the patients (98.6%) received aprepitant in capsule form in a dose of 40 mg (97.9%). Seventeen patients (11.8%) had PONV or received antiemetic agents postoperatively. There were no unplanned admissions related to PONV. No adverse effects related to aprepitant were noted. Conclusions: Aprepitant was effectively introduced to the preoperative regimen as an additional agent for the prevention of PONV. The overall tolerability and efficacy of aprepitant was similar to previous studies, even in a patient population at high risk for PONV. J Curr Surg. 2022;12(1):1-6 doi: https://doi.org/10.14740/jcs457
- 1 March 2022
- Published by Elmer Press, Inc. in Journal of Current Surgery
- Vol. 12 (1) , 1-6
Open AccessPreoperative Administration of Aprepitant to Prevent Postoperative Nausea and Vomiting in Children
Background: Aprepitant (Emend®), a neurokinin-receptor antagonist, has seen increased use in the treatment of nausea and vomiting in various clinical scenarios. To date, there are limited data regarding its use in the pediatric population. We retrospectively reviewed our experience with aprepitant after its addition to the operating room formulary for prevention of postoperative nausea and vomiting (PONV). Methods: The anesthetic records of patients who received aprepitant were retrospectively reviewed. Demographic, surgical, medication, and efficacy data were retrieved. Results: The study cohort included 144 patients ranging in age from 7 to 17 years and in weight from 24.7 to 208.9 kg. The most common surgical procedures included gastrointestinal surgery, orthopedic surgery, and otolaryngologic procedures. Reasons for the administration of aprepitant included PONV prophylaxis due to risk factors such as type of surgery, duration of surgery, previous history of significant PONV, female gender, and family history of PONV. The majority of the patients (98.6%) received aprepitant in capsule form in a dose of 40 mg (97.9%). Seventeen patients (11.8%) had PONV or received antiemetic agents postoperatively. There were no unplanned admissions related to PONV. No adverse effects related to aprepitant were noted. Conclusions: Aprepitant was effectively introduced to the preoperative regimen as an additional agent for the prevention of PONV. The overall tolerability and efficacy of aprepitant was similar to previous studies, even in a patient population at high risk for PONV. J Curr Surg. 2022;12(1):1-6 doi: https://doi.org/10.14740/jcs457